Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: A case report and review of the literature

Clinical and Experimental Dermatology

Volumn 30, Issue 4, 2005, Pages 391-394

  Alexandrescu, Doru T ^a   Koulova, L ^a   Wiernik, P H ^a  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN G; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; SYNDECAN 1; THALIDOMIDE; VINCRISTINE;

ADULT; AFRICAN AMERICAN; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 16; CHROMOSOME 18; CHROMOSOME 19; CHROMOSOME 20; CHROMOSOME 21; CHROMOSOME 4; CHROMOSOME 6; CHROMOSOME 9; CHROMOSOME DELETION; DEATH; DISEASE COURSE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; KARYOTYPING; MALE; MONOSOMY; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PLASMACYTOSIS; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SKIN BIOPSY; SKIN MANIFESTATION; TRISOMY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, PLASMACYTIC; LEUKEMIC INFILTRATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SKIN; THALIDOMIDE;

EID: 20644432438     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01788.x     Document Type: Review

References (10)

1. Rawstron A, Barrans S, Blythe D et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Hematol 1999; 104: 138-43.
2. Avigdor A, Raanani P, Levi I et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001; 42: 683-7.
3. Yang Y, Yacoby S, Liu W et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100: 610-7.
4. Bayer-Garner IB, Joseph L, Sanderson RD et al. Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytoma. Cutan Pathol 2003; 30: 18-22.
5. Tsutani H, Sugiyama T, Shimizu S et al. Discordant LFA-1/ICAM-1 expression in a case of a secondary plasma cell leukemia associated with subcutaneous plasmacytoma. Am J Hematol 1993; 42: 299-304.
6. Pellat-Decheunyck C, Barille S, Jego G et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977-82.
7. Sahara N, Takeshita A, Shigeno K et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Hematol 2002; 117: 882-5.
8. Hideshima T, Chauhan D, Podar K et al. Novel therapies targeting the myeloma cell and its bone marrow environment. Semin Oncol 2001; 28: 607-12.
9. Blade J, Perales M, Rosinol L et al. Thalidomide in multiple myelonma: lack of response of soft-tissue plasmacytomas. Br J Hematol 2001; 113: 422-4.
10. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q. chrosomal abnormalities are not randomly distributed, but correlate with natural history immunological features and clinical presentation. Blood 2002; 99: 2185-91.